Chrysea Acquires Rodon Biologics

Chrysea Limited has announced the acquisition of Rodon Biologics from Iberfar Group. Rodon is a company with over 20 years of expertise in biomanufacturing and development of biological products. This acquisition will allow Chrysea to integrate a variety of skills and know-how for protein engineering, cell-line development, precision fermentation, downstream processing, formulation, analytics and production into its existing capabilities.

Rodon Biologics will continue to operate independently, serving its wide range of existing and new clients in addition to Chrysea’s projects. This acquisition will provide Chrysea with a platform to strengthen its plans for bringing to market its products developed by synthetic biology and Rodon Biologics will access advanced synthetic biology capabilities and tools from Chrysea to broaden its offering to the biopharmaceutical industry.

The team at Rodon Biologics has a well-established track-record in the development of biopharmaceuticals such as novel antibody based multispecifc formats, cytokines and growth factors as well as added-value consumer products, enzymes and food ingredients and supplements. This will further enhance Chrysea's recent expansion of product platforms for the development of rare and hard-to-source ingredients, which are not economically attainable nor sustainably produced using chemical synthesis.

The company reaffirms its dedication to pioneering innovative solutions and propelling progress in the formulation, production, and market introduction of products that are produced through sustainable and eco-friendly methods. Moreover, this move significantly enhances Chrysea's development capabilities in the biopharmaceutical industry by leveraging its existing state-of-the-art synthetic biology know-how and technologies. “Chrysea's acquisition of Rodon Biologics represents a pivotal moment in its strategic growth and expansion trajectory. This acquisition places Chrysea at a vantage point to address the surging demand for development and biomanufacturing within the biopharmaceutical and synthetic biology sectors”, said Pedro de Noronha Pissarra, Chief Executive Officer of Chrysea Limited.

The Rodon acquisition was also supported by Juvenescence Limited (“Juvenescence”). “We're delighted to continue our support for Chrysea on its mission to develop high-quality and impactful products. This acquisition represents a truly remarkable opportunity", said Richard Marshall, Chief Executive Officer of Juvenescence.